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Abstract
Nitric oxide (NO) is a unique and nearly ubiquitous molecule that is
widely utilized as a signaling molecule in cells throughout the body.
NO is highly diffusible, labile, and multiply reactive, suiting it well
for its role as an important regulator of a number of diverse biologic
processes, including vascular tone and permeability, platelet
adhesion, neurotransmission, and mitochondrial respiration. NO
can protect cells against antioxidant injury, can inhibit leukocyte
adhesion, and can participate in antimicrobial defense, but can
also have deleterious effects, including inhibition of enzyme
function, promotion of DNA damage, and activation of inflammatory
processes. This molecule’s chemistry dictates its biologic activity,
which can be both direct and indirect. In addition, NO has bimodal
effects in a number of cells, maintaining homeostasis at low doses,
and participating in pathophysiology in others. Perturbation of NO
regulation is involved in the most important and prevalent disease
processes in critical care units, including sepsis, acute lung injury,
and multiple organ failure. Given that NO is ubiquitous, highly
diffusible, and promiscuously reactive, its regulation is complex.
The NO concentration, kinetics, and localization, both inside and
outside the cell, are clearly crucial factors. In the present update
we review a selection of studies that have yielded important
information on these complex but important issues. Interpretation
of these and other studies aimed at elucidating physiologic and
pathophysiologic roles of NO must take this complexity into
account. A full review of the role of NO in these diseases is beyond
the scope of the current manuscript; the present article will focus
on recent advances in understanding the complex role of NO in
health and disease.
Introduction
Nitric oxide (NO) is a unique and nearly ubiquitous molecule
that is widely utilized as a signaling molecule in cells through-
out the body. NO is a highly diffusible, labile, and multiply
reactive free radical gas, suiting it well for its role as an
important regulator of a number of diverse biologic
processes, including vascular tone and permeability, platelet
adhesion, neurotransmission, and mitochondrial respiration.
NO can protect cells against antioxidant injury, can inhibit
leukocyte adhesion, and can participate in antimicrobial
defense, but can also have deleterious effects, including
inhibition of enzyme function, promotion of DNA damage, and
activation of inflammatory processes.
The chemistry of NO dictates its biologic activity. NO has
direct effects on metal complexes and alkyl radicals – inclu-
ding, most importantly, guanylate cyclase, cytochromes, and
lipid radicals – but also has indirect effects through nitration
to form nitrotyrosine, through nitrosation to form nitrosothiols
and nitrosamines, and through combination with oxidative
radicals, the most important of which is peroxynitrite (see
Figure 1) [1,2]. NO acts as a second messenger by activating
soluble guanylate cyclase and participating in signal trans-
duction pathways involving cyclic GMP, but also operates
independently of guanylate cyclase [2]. NO regulates the
cytoplasmic redox balance and also signal transduction,
either by regulating cytoplasmic and mitochondrial calcium
signals or by post-translational modification of intracellular
proteins. NO is a bifunctional modulator of cell death,
capable of either stimulating or inhibiting apoptosis.
Given that NO is ubiquitous, highly diffusible, and promis-
cuously reactive, one might well ask how it is regulated with
precision. The answers are complex and remain to be fully
elucidated, but the NO concentration, kinetics, and
localization, both inside and outside the cell, are clearly
crucial factors [2]. In the present update we shall review a
selection of studies that have yielded important information
on these complex but important issues. Interpretation of these
and other studies aimed at elucidating physiologic and patho-
physiologic roles of NO must take this complexity into account.
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Perturbation of NO regulation is involved in the most
important and prevalent disease processes in critical care
units, including sepsis, acute lung injury, and multiple organ
failure [3]. A full review of the role of NO in these diseases is
beyond the scope of the current manuscript; the present
article will focus on recent advances in understanding the
complex role of NO in health and disease.
Nitric oxide synthases
NO is synthesized from L-arginine and oxygen by the enzyme
nitric oxide synthase (NOS). At least three distinct isoforms of
NOS are known, including neuronal nitric oxide synthase
(nNOS, NOS1), inducible nitric oxide synthase (iNOS,
NOS2), and endothelial nitric oxide synthase (eNOS, NOS3)
enzymes. Whereas iNOS activity depends on transcription,
eNOS and nNOS are constitutively expressed and are
activated by elevated intracellular calcium; iNOS gene
expression is modulated by inflammatory mediators, such as
the cytokines TNFα, IFNγ, and lipopolysaccharide, which
activate transcription factors such as NFκB or activator
protein 1; and the iNOS isoform generates much larger
quantities of NO (nanomolar range) than constitutive NOS
isoforms (picomolar range) [4].
Some of the diversity of cellular responses to NO can be
explained by different actions of NO at different concentration
levels [2]. For example, physiological actions due to cyclic-
GMP-mediated processes predominate at NO concen-
trations ranging from 1 to 30 nM, tissue repair processes
including AKT phosphorylation (30 to 100 nM) and hypoxia
inducible factor-1 stabilization (100 to 300 nM) at somewhat
higher concentrations, antipathogenic and tumoricidal
responses from 300 to 800 nM, and nitrosative stress at
concentrations >1 μM [2]. In general, lower concentrations
promote cell survival and proliferation, and higher concen-
trations favor cell cycle arrest, apoptosis, and senescence.
Interactions of NO with other reactive species can modulate
its concentrations and thus change its cellular profile [2].
Another important factor contributing to the diversity of NO
action is localization within the cell. For example, eNOS
binding to the cell membrane anchoring protein caveolin
decreases enzyme activity, whereas binding to heat shock
protein 90 increases its activity [5]. In addition, different NOS
enzymes localize to different portions of the cell, allowing for
local action and regulation. In the heart, for example, nNOS is
present in presynaptic nerves and the cardiomyocyte sarco-
plasmic reticulum, eNOS is localized in caveolae of endo-
thelial cells and in myocytes at the T-tube sarcoplasmic
reticulum, and iNOS is induced in the myocyte cytoplasm [6].
NO localization allows for potential modulation of intracellular
calcium concentrations through interaction with ryanodine
receptors, which are also localized to T-tubules [6].
Another isoform, a mitochondrial variant of NOS, was
described recently. Whether this is a distinct NOS isoform
coded by mitochondrial DNA or whether it represents nNOS
translocated to mitochondria with specific post-translational
modifications is unclear [7]. This mitochondrial variant of
NOS is bound to the mitochondrial PDZ domains of
cytochrome oxidase and to complex I [5], and this localization
allows the released NO to modulate mitochondrial respiration
[7]. The source of mitochondrial NO also remains somewhat
controversial; diffusion of cytosolic NO into the mitochondria
may also contribute to mitochondrial NO concentrations. In
any event, mitochondrial NO is an important regulator of
mitochondrial respiration. In hypoxic conditions, mitochondrial
NO could be maintained either by stimulation of NOS or from
the reduction of nitrite by cytochrome oxidase [7]. In other
pathologic conditions, such as sepsis, diffusion of NO
produced by cytosolic iNOS may result in an increased
mitochondrial NO concentration [7].
As nNOS has been increasingly studied, its importance in
regulation of the circulatory system – not only by modulating
neurotransmission, but also acting on its own – has become
more apparent [8]. nNOS is present not only in sympathetic
and parasympathetic nerve terminals, but also in cardiac
myocytes, where it localizes to the sarcoplasmic reticulum
and modulates calcium influx [6]. nNOS was recently shown
Figure 1
Direct and indirect actions of nitric oxide. Nitric oxide (NO) has direct
effects on metal complexes and alkyl radicals, including guanylate
cyclase, cytochromes, and lipid radicals. NO also has indirect actions
through nitration to form nitrotyrosine, through nitrosation to form
nitrosothiols and nitrosamines, and through combination with oxidative
radicals, with the potential for subsequent peroxidation of lipids, DNA
strand breaks, and hydroxylation. eNOS, endothelial NO synthase;
iNOS, inducible NO synthase; nNOS, neuronal NO synthase; O2
–,
superoxide. Reprinted from Free Radical Biology and Medicine, 45(1),
Douglas D. Thomas, Lisa A. Ridnour, Jeffrey S. Isenberg, Wilmarie
Flores-Santana, Christopher H. Switzer, Sonia Donzelli, Perwez
Hussain, Cecilia Vecoli, Nazareno Paolocci, Stefan Ambs, Carol A.
Colton, Curtis C. Harris, David D. Roberts and David A. Wink, The
chemical biology of nitric oxide: Implications in cellular signaling, 14
Pages, Copyright (2008), with permission from Elsevierto decrease endotoxin-induced TNF synthesis in cultured
cardiac myocytes by inhibiting L-type calcium channel-depen-
dent ERK signaling, suggesting nNOS might modulate
inflammatory signaling [9]. On the other hand, nNOS
appeared to play a role in mediating impaired microcirculatory
responses in sepsis. In a rat cecal ligation and puncture
(CLP) model, both inhibition and deletion of nNOS restored
eNOS signaling and vasodilatory responses and increased
downstream capillary red blood cell velocity [10]. Studies of
the role of nNOS isoforms in the pathophysiology of disease
are likely to proliferate as the importance of its role, both by
producing NO and also by modulating other NOS isoforms,
gains recognition.
Uncoupling of endothelial nitric oxide synthase
Although eNOS exists as a homodimer that produces NO
from  L-arginine, under certain conditions it can become
uncoupled – to become a monomer that produces not NO,
but the oxidative free radical superoxide (O2
–) [11]. The most
prominent of these conditions is a lack of availability of
tetrahydrobiopterin (BH4), which usually results from its
oxidation to dihydrobiopterin under conditions of oxidative
stress. The resultant oxidative stress from O2
– production can
further promote NOS uncoupling, a forward feedback loop
that can magnify the amount of oxidative stress within the cell.
Other conditions that can uncouple eNOS include relative
deficiency of its substrate, arginine and the presence of an
endogenous competitive NOS inhibitor, asymmetric dimethyl-
L-arginine (ADMA) [11].
The pathophysiology of eNOS uncoupling suggests several
possible approaches to restore eNOS functionality in clinical
situations, including administration of BH4, of folic acid to
increase intracellular BH4 levels, or of exogenous arginine. In
sepsis, there was concern that arginine treatment would
provide a substrate for increased NO production from iNOS,
but in fact arginine has been given to patients with sepsis
without worsening hemodynamics, and arginine has been
proposed as a component of immunomodulatory nutritional
formulations [12]. More clinical trials are needed to evaluate
the potential of these therapies.
Nitrosothiols
S-nitrosylation refers to the reaction of NO with sulfhydryl
groups on critical protein cysteine residues, often the site of
disulfide bonds. S-nitrosothiol species have been implicated
in controlling oxygen delivery to tissues, and modulating both
the function and activity of transcription factors, enzymes, and
ion channels. S-nitrosylation may also be a mechanism for
localizing NO activity within the cell. Recent evidence in
cardiac myocytes suggests that S-nitrosylated proteins
located in the vicinity of phosphatases regulate calcium
sensitivity and reuptake, modulating both systolic and
diastolic function [13]. Interestingly, NOS itself can be
nitrated and nitrosylated; in the case of the nNOS isoform,
this decreases enzyme activity [14].
Intravascular proteins such as albumin and also cysteine 93
on the β subunit of hemoglobin can be S-nitrosylated, and
this may serve to buffer excess NO, ameliorating potential
toxic effects of overabundant NO release. S-nitrosylation may
also allow NO to exert distant effects, and also to transport
NO bioactivity in response to vasoregulatory signals in areas
that may require increased blood flow. In fact, S-nitrosylated
human serum albumin has recently been tested as a means of
NO supplementation, and has been shown to reduce lung
injury and to prolong survival in a rat model of endotoxin
infusion [15].
Nitrite
Nitrite has recently been shown to be a reservoir of NO in the
circulation, and may in fact be the most important such
reservoir. Nitrite is uniquely poised to behave as a carrier of
NO bioactivity in the systemic circulation due to its relative
stability and its ability to be reduced to NO. Nitrite converts to
NO under acidemic and ischemic conditions, ensuring NO
production in situations in which oxygen-dependent NOS
enzyme activities may be compromised and in areas in which
increased blood flow would be desirable [16]. Nitrite
reduction to NO can therefore be an important regulator of
regional blood flow.
A recent set of careful studies in normal volunteers has
broadened our knowledge about the kinetics, potency, and
mechanisms of action of nitrite; its vasodilatory effects do not
appear to be susceptible to tolerance, which sets this anion
apart from the organic nitrates [17]. Accumulating evidence
has suggested that nitrite infusion may represent a
therapeutic alternative for diseases associated with regional
hypoxia and vasoconstriction, including sickle cell disease,
pulmonary hypertension, and stroke, and clinical trials are
currently underway.
Nitric oxide synthase inhibition
NO overproduction has been implicated in the pathogenesis
of a number of diseases, and so therapeutic strategies aimed
at blocking NOS have been tested both in preclinical models
and in clinical trials. Interpretation of these studies,
particularly those in animal models, has been complicated by
a number of factors, several of which merit discussion. The
first factor is isoform specificity. Many pharmacologic NOS
inhibitors are arginine analogs, and these may inhibit more
than one NOS isoform. Structurally distinct NOS isoform
inhibitors can overcome this limitation, but may have effects
unrelated to NO synthesis. More broadly, although the
different localization and kinetics of different isoforms confer
a degree of specificity of function, there is always some
degree of overlap. In the setting of experiments with knockout
animals, one isoform may potentially take over the functions of
another – a difficulty that may be mitigated, but not elimi-
nated, by use of tissue specific promoters, conditional knock-
outs, or multiple knockouts. This complicates not only inter-
pretation of experiments, but also of disease pathophysiology.
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particularly reactive oxygen intermediates. Many of these
reactions are concentration-dependent, which means that
they can and do differ in different parts of the cell [5]. For
example, when local NO levels exceed O2
– concentrations,
NO tends to reduce oxidative stress. When O2
– levels
exceed NO concentrations, O2
– reduces the amount of
bioavailable NO. When local NO and O2
– levels are roughly
equimolar, however, the highly reactive and toxic radical
peroxynitrite is formed, with kinetics substantially faster than
dismutation of O2
– by superoxide dismutase (see Figure 2)
[18]. Peroxynitrite can rapidly oxidize the active NOS cofactor
BH4 to inactive dihydrobiopterin, uncoupling eNOS. The
formation of peroxynitrite when concentrations of NO and
O2
– are similar may be the explanation for some settings,
prominently those in which reperfusion injury plays a role, in
which both NO inhibition and NO donors appear to have
beneficial effects [18], as altering NO concentration in either
direction would be expected to reduce peroxynitrite levels.
A third, and to some extent related, factor is that NO action is
often bimodal, depending on the concentration. In cardiac
myocytes, for example, NO can have either positive or
negative inotropic effects, depending on the concentration
(see Figure 3) [19]. NO at low concentrations stimulates
protein kinase A, increasing contractility by opening sarco-
lemmal calcium channels and stimulating ryanodine receptors.
At high concentrations, however, actions of NO and cyclic
GMP decrease contractility by hyperpolarizing the plasma
membrane, decreasing calcium influx, and also by decreasing
the sensitivity of troponin T to calcium [19].
Given this complexity, it becomes less surprising that NOS
inhibition can have different effects in different settings, and
that sometimes both NOS inhibition and NO donors can have
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Figure 2
Reaction of nitric oxide with oxidative radicals is dependent on
concentration and distance. When local nitric oxide (NO) levels exceed
concentrations of reactant oxidant species, NO tends to reduce
oxidative stress. When oxidant species exceed NO concentrations,
they reduce the amount of bioavailable NO. When local NO and
superoxide (O2
–) levels are roughly equimolar, however, the highly
reactive and toxic radical peroxynitrite (ONOO–) is formed.
Figure 3
Bimodal actions of nitric oxide in cardiac myocytes. (a) At low
concentrations, nitric oxide (NO) stimulates adenylate cyclase (AC)
and acts through guanylate cyclase (GC) to inhibit phosphodiesterase
(PDE), both of which increase cAMP levels, thus stimulating cAMP-
dependent protein kinase A (PKA). PKA increases contractility by
opening voltage-operated calcium channels (VOCs) on the plasma
membrane and by stimulating ryanodine receptors (RyRs) on the
sarcoplasmic reticulum (SR). (b) At high concentrations, however, NO
produces much larger amounts of cyclic GMP (cGMP), which
stimulates the cGMP-dependent protein kinase G (PKG). PKG
decreases contractility by hyperpolarizing the plasma membrane,
decreasing calcium influx through voltage-sensitive channels, and also
by decreasing sensitivity of troponin T to calcium [19]. Reprinted from
Life Sciences, 81(10), R. Rastaldo, P. Pagliaro, S. Cappello, C. Penna,
D. Mancardi, N. Westerhof and G. Losano, Nitric oxide and cardiac
function, 15 Pages, Copyright (2007), with permission from Elseviersimilar effects in the same setting. Despite this complexity,
NO inhibition can provide useful insights into disease
pathophysiology, and may have therapeutic potential in some
settings as well.
Sepsis
NO overproduction due to activation by cytokine-inducible
NOS has been implicated in the pathophysiology of micro-
circulatory failure and organ dysfunction in sepsis, and NOS
inhibition was shown to prevent vasodilation and hypotension
in several experimental models [20-22]. The nonspecific NOS
inhibitor  NG-methyl-L-arginine (L-NMMA), however, did not
improve mortality in a multicenter, randomized, double-blind,
placebo-controlled trial of patients with septic shock,
although hypotension was improved [23]. Precisely why this
clinical trial failed is not entirely certain, but concerns have
been expressed about the dosage, patient selection, titration
to maintain blood pressure, as well as the nonspecific nature
of the NOS inhibitor used. Despite the lack of benefit of NOS
inhibition in this large clinical trial, studies of NO in sepsis
continue to yield important pathophysiologic insights – and a
role for manipulation of NO in the treatment of sepsis has not
yet been ruled out definitively.
One recent study suggested that nNOS plays a more
important role in sepsis than previously recognized. Mice
deficient in nNOS had impaired bacterial clearance and
decreased survival in a CLP model of sepsis; the results were
similar when wild-type mice were treated with a selective
nNOS inhibitor, suggesting that nNOS may have a protective
role in sepsis [24].
The role of the other constitutive NOS isoform in sepsis is
also being elucidated. Nonselective NOS inhibition is known
to increase both leukocyte rolling and adhesion in a rat CLP
model of sepsis [25], suggesting that eNOS may also have a
protective role. In a recent study, mice with cardiomyocyte-
specific overexpression of eNOS were protected from
myocardial dysfunction associated with endotoxin infusion
and also with polymicrobial bacterial challenge, an effect that
appeared to be mediated by preserved myofilament sensitivity
to calcium [26]. In an interesting clinical study, an eNOS
polymorphism that is associated with decreased basal NO
production and hypertension was associated with lower
blood pressures in patients with Escherichia coli bacteremia,
although this effect was not seen with Gram-positive
bacteremia, and the eNOS polymorphism did not correlate
with outcome in this relatively small study (147 patients) [27].
Genetic studies of this size are probably not robust enough
to permit firm conclusions and the results require confir-
mation in other populations, but they do have the potential to
generate provocative hypotheses.
Several recent studies have contributed to elucidating the
role of iNOS in the pathophysiology of sepsis. In a rat model
of CLP-induced sepsis, selective pharmacologic iNOS
inhibition increased capillary red cell velocity and increased
local skeletal muscle tissue oxygen consumption, although
NOS inhibition did not decrease the number of capillaries
with stopped flow [28]. In a murine CLP model, iNOS
knockout mice and wild-type mice treated with a selective
iNOS inhibitor showed a decrease in microvascular leakage
without a significant decrease in abnormal leukocyte rolling
and adhesion [29]. This discordance between adhesion of
leukocytes and microvascular leakage suggested that these
are regulated independently, and that increased vascular
permeability in sepsis is dependent on iNOS induction, but
that leukocyte activation occurs with or without iNOS. Studies
such as these suggest that attenuation of the protective
effects of constitutive NOS isoforms may help explain the
failure of this therapy when applied in patients with septic
shock, and that selective iNOS inhibition might have potential
salutary effects, but the impact of such an approach remains
to be elucidated by appropriately designed clinical trials.
Since NOS inhibition in septic shock is potentially a double-
edged sword, scavenging excess NO has been proposed as
another potential approach to counteract the effects of NO
production in sepsis. This approach has the theoretical
advantage of being most effective in the areas of largest NO
overproduction. A chemically modified human-derived hemo-
globin conjugate pyridoxalated hemoglobin polyoxyethylene
selectively scavenges excessive NO without interfering with
NOS expression or activity. Its potential to increase systemic
blood pressure and to reduce vasopressor and ventilation
needs without adversely affecting cardiac output, organ
function, and survival provided the impetus for a multicenter,
randomized, placebo-controlled clinical trial in patients with
distributive shock. Although the overall 28-day mortality was
similar, a rapid increase in blood pressure and rapid
withdrawal of vasopressors were observed in these patients,
and survivors treated with pyridoxalated hemoglobin
polyoxyethylene spent less time on mechanical ventilation
[30]. This new approach to NO modulation may be useful in
distributive shock states, but larger trials with hard outcomes
will be needed.
Other studies have suggested that NOS inhibition might be
used in combination with other approaches. In a porcine
model of continuous infusion of Pseudomonas aeruginosa,
selective NOS inhibition in conjunction with oxygen free
radical scavenging improved sepsis-induced microcirculatory
dysfunction, hepatosplanchnic dysfunction, metabolic dys-
function, and renal dysfunction [31]. The level of production
of reactive oxygen intermediates by cultured endothelial cells
when exposed to sera from patients with severe sepsis was
recently shown to correlate with mortality [32]. Also, as noted
above, oxidative stress contributes to uncoupling of eNOS,
increasing formation of reactive oxygen intermediates [11].
Addressing both oxidative and nitrosative stress, by reducing
formation of peroxynitrite and other toxic intermediates, might
have therapeutic promise.
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The classic hemodynamic profile for patients with cardiogenic
shock consists of low cardiac output and high systemic
vascular resistance, but wide variations in left ventricular
ejection fraction and systemic vascular resistance in patients
with cardiogenic shock suggest that pathophysiologic
mechanisms of cardiogenic shock may vary among patients.
About one-fifth of patients with cardiogenic shock compli-
cating myocardial infarction in the SHOCK trial had clinical
evidence of a systemic inflammatory response syndrome,
marked by fever, leukocytosis and low systemic vascular
resistance [33]. This observation has led to an expansion of
the classic paradigm to include the possibility of the contri-
bution of inflammatory responses to vasodilation and
myocardial stunning, leading clinically to persistence of shock
[34]. Activation of iNOS with production of NO and peroxy-
nitrite was proposed as one potential mechanism [34], and
so NOS inhibition was proposed as a therapeutic strategy for
patients with persistent shock despite an open infarct artery.
After preliminary studies using the NOS inhibitor L-NMMA
showed promising hemodynamic effects, with increased
blood pressure and urine output [35], a phase III randomized
trial to study L-NMMA in patients with cardiogenic shock –
the Tilarginine Acetate Injection Randomized International
Study in Unstable AMI Patients/Cardiogenic Shock
(TRIUMPH) trial – was initiated. The results of this trial have
recently been published [36]. Although L-NMMA increased
blood pressure significantly at 2 hours, there was no effect on
either the primary outcome, the 30-day mortality, or the
secondary outcomes of shock resolution and duration and
6-month mortality [36]. Whether the failure of this clinical trial
represents the failure of the strategy of NOS inhibition or
whether factors such as dosing, timing, and NOS inhibitor
selectivity were important is not yet entirely certain.
Acute lung injury
Acute lung injury is another area in which both oxidative
stress and nitrosative stress play a role. As in other fields,
different isoforms are involved and play different roles. In a
sheep model of combined burn injury and Pseudomonas
pneumonia in which selective iNOS inhibition had previously
been shown to improve gas exchange, a new study showed
that selective nNOS inhibition improved pulmonary gas
exchange, lung compliance, and lung edema [37]. nNOS
inhibition also decreased nitrotyrosine in lung tissue, a marker
of peroxynitrite formation, and, interestingly, diminished levels
of iNOS protein in the lung [37]. It was speculated that
nNOS was a trigger for iNOS formation in this model, but
direct evidence was not provided. Additional investigations in
the same model examined early nNOS inhibition combined
with delayed iNOS inhibition, and found a similar
improvement in pulmonary gas exchange and injury score,
along with decreased inflammation, although lung edema was
not decreased in this study [38]. Support for the notion that
peroxynitrite is a pivotal pathogenetic mediator in lung injury
was provided when a metalloporphyrinic peroxynitrite
decomposition catalyst was shown to prevent IL-2-induced
vascular leakage in an ovine model [39].
Interestingly – despite the fact that pathophysiologic con-
siderations, bolstered by clinical association studies, suggest
that high levels of NO, either by themselves or in combination
with reactive oxygen intermediates, mediate pulmonary damage
in acute lung injury – when baseline levels of urinary NO
metabolites were examined in 566 patients from the
multicenter ARDSNET trial comparing low tidal volumes with
high tidal volumes in acute lung injury, higher urine NO was
associated with better clinical outcomes, including lower
mortality and more organ-failure-free days [40]. There are a
number of potential explanations for this surprising finding.
Urine NO may not accurately reflect pulmonary NO levels, or
higher baseline NO levels may have been a marker for less
severe injury. An alternative explanation, however, is that NO
has beneficial effects, either in the lung or in organs other
than the lung. Potential mechanisms include NO scavenging of
reactive oxygen species, microcirculatory vasodilation, and
decreased platelet and leukocyte adhesion to the endothelium.
Nitric oxide and diabetes
Failure of NO signaling is an important component of the
pathogenesis of endothelial dysfunction in patients with
diabetes, leading to accelerated atherosclerosis and
vascular events. Hyperglycemia can induce overproduction
of O2
–, can decrease NO production, and can damage
endothelial cells, suggesting a mechanism by which glucose
contributes to endothelial dysfunction in diabetes [41].
Insulin resistance also plays an important role [41]. Recent
studies have shown that endothelial dysfunction in diabetes
may also be related to production of ADMA, by competitive
inhibition of arginine binding to NOS and by uncoupling of
eNOS [42]. Studies have begun to explore the role of
dimethylarginine dimethylaminohydrolase, an enzyme
primarily responsible for ADMA degradation. Levels of
dimethylarginine dimethylaminohydrolase are decreased in
diabetes, particularly in the kidney [43]. Strategies to
enhance dimethylarginine dimethylaminohydrolase activity
may have therapeutic potential to modulate ADMA levels in
this and other conditions.
Diabetes can also cause iNOS induction, with resultant
nitrosative stress. A recent study in streptozotocin-induced
diabetes in rats showed overexpression of iNOS in the
diabetic liver and kidney, suggesting a potential role for iNOS
in mediating organ dysfunction [44]. iNOS may also mediate
insulin resistance in inflammatory processes, impairing insulin
signaling and worsening hyperglycemia.
Nitric oxide and cellular energy metabolism
NO is known to modulate mitochondrial function, generally
downregulating mitochondrial energy production by
reversibly inhibiting cytochrome c oxidase, the terminal
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This can be advantageous in a phenomenon known as
ischemic preconditioning, in which brief periods of ischemia
are protective against subsequent episodes of sustained
ischemia followed by reperfusion. A recent study showed
that cardiomyocyte-specific NOS overexpression was
protective against ischemia–reperfusion injury, thus
bolstering the role of NO in preconditioning [46]. The
mechanisms have not been completely characterized, but
they appear to include NO-stimulated increases in protein
kinase C, and perhaps opening of mitochondrial KATP
channels. Very high levels of NO, such as those that can
occur with inflammation after ischemia/reperfusion, however,
can cause opening of the mitochondrial permeability
transition pore, with uncoupling of oxidative phosphorylation,
dissipation of membrane gradients, membrane swelling, and
cell death. This is another example of a biphasic effect of
NO, with beneficial effects at low doses and deleterious
effects at high doses.
The initial phases of sepsis are characterized by impaired
hemodynamics, but later organ failure can occur despite
restoration of an adequate blood pressure and cardiac
output. Oxygen delivery does not appear to be the limiting
factor in multiple organ failure, suggesting a defect in cellular
oxygen use, which in turn would point to mitochondrial
dysfunction as a pathogenic mechanism in sepsis-induced
organ failure [47]. This hypothesis is supported both by
laboratory investigations showing progressive mitochondrial
dysfunction with ATP depletion and respiratory chain complex
I inhibition in animal models of sepsis [48] and by a study in
patients with septic shock, in which skeletal muscle biopsies
demonstrated similar ATP depletion and respiratory chain
complex I inhibition [49]. In both settings, the degree of
mitochondrial dysfunction correlated with the severity of
illness and with eventual outcome [48,49].
NO contributes to mitochondrial dysfunction in sepsis, in part
by nitrating regulatory proteins. Oxidative stress contributes
as well, and in this dysfunction, as in other areas, an additive
effect can occur in which NO-induced mitochondrial injury
causes inefficient mitochondrial respiration, with increased
production of oxidant species. In this context, a recent study
demonstrated that ADMA-induced uncoupling of eNOS led
to increased peroxynitrite formation and mitochondrial
dysfunction in pulmonary endothelial cells [42].
On the contrary, it has been speculated that NO may play an
adaptive role in some situations, modulating oxidative
phosphorylation at a time when mitochondrial efficiency is
compromised [50]. While this may potentially protect the cell
by simultaneously decreasing mitochondrial oxygen utilization
and promoting repair processes, it could also contribute to
bioenergetic failure. The balance between beneficial and
pathogenic effects may differ in different organs and at
different times in the course of sepsis.
Nitric oxide donors and the microcirculation
As we have seen, explorations of the complex role of NO in
health and disease have continued to highlight bimodal
actions of NO, generally with protective actions at low levels
and deleterious actions at higher levels. The potential for NO
to interact with other reactive species is also concentration-
dependent – and, perhaps most importantly, localization of
NO is a crucial determinant of its effects, both within cells
and in tissues and organs. This is perhaps most strikingly
observed in the microvasculature, where regional hetero-
geneity in flow may lead to pathologic events even if the
global hemodynamic parameters remain normal. In sepsis, for
example, microvascular heterogeneity documented by ortho-
gonal polarization spectral imaging was recently shown to be
abnormal in septic patients, and the abnormalities were more
pronounced in nonsurvivors than in survivors [51].
The potential for NO to have beneficial effects has provided
the rationale for trials of administration of NO donors in
various diseases. Interest has been especially keen in sepsis,
in which the microcirculatory pathology plays a crucial role
and where local administration of vasodilators might be
expected to augment microcirculatory flow. Two recent
experimental studies demonstrate how NO donors have the
potential to improve splanchnic microcirculation in sepsis. In
a resuscitated porcine model of Pseudomonas adminis-
tration, the NO donor sodium nitroprusside increased the ileal
mucosal and hepatic microcirculatory blood flows [52].
Another NO donor, SIN-1, was tested in a porcine model of
endotoxemia, with use of tonometry to measure splanchnic
pCO2 along with porphyrin phosphorescence to assess
microvascular oxygen pressures, which allowed for
exploration of mechanisms of NO action [53]. The NO donor
normalized mucosal oxygen tension, but improved serosal
oxygen tension only when given along with fluids –
suggesting that NO along with appropriate resuscitation can
redistribute, and thereby improve, splanchnic microvascular
perfusion [53].
In two clinical studies of sepsis patients utilizing orthogonal
polarization spectral imaging, the sepsis-induced impairment
of sublingual microcirculatory blood flow was reversed with
topical administration of acetylcholine – suggesting that the
endothelium was still NO responsive [54] – and with
intravenous nitroglycerin [55]. Precisely how to deliver NO
donors in the clinical setting remains an issue, as they have
the potential to exacerbate hypotension in shock states. A
study in a mouse model of cardiac ischemia and reperfusion
showed that NO inhalation was protective, and produced an
increase in the concentration of NO metabolites in the lung,
the liver, the heart, and the brain [56], suggesting that inhaled
NO can have a systemic effect, perhaps via nitrosothiols,
nitrosamine, or increased generation of nitrite.
Novel agents to rescue the microcirculation may prove to be
a cutting-edge strategy to optimize tissue perfusion in shock.
Available online http://ccforum.com/content/13/4/218
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The hypothesis that inhaled NO administration will improve
microcirculatory perfusion without significant impairment of
systemic hemodynamics is supportable on the basis of
current data, but will need to be tested in clinical trials. Our
bias is that indices of microcirculatory perfusion may yield
physiologic information that macrocirculatory indices cannot,
and help to guide such therapy. Accordingly, we are initiating
a randomized clinical trial to test the efficacy of inhaled NO in
improving microcirculatory perfusion and organ failure in
septic patients with persistent microcirculatory dysfunction
(as assessed by sidestream darkfield imaging of the
sublingual circulation) after early goal-directed resuscitation
has been successfully accomplished [3]. Since it is possible
that NO will improve microcirculatory perfusion without
impacting organ failure, or will improve organ failure without
an increase in perfusion, this trial may allow for inferences
about the relative roles of microcirculatory perfusion and
other potential mechanisms, such as inflammation and
mitochondrial function, in the development of organ failure in
sepsis. Regardless of the outcome of this trial, we look
forward to further studies to translate mechanistic and
therapeutic insights from animal studies into the clinical area.
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